



## Lab Resource: Multiple Stem Cell Lines

## Lymphoblast-derived hiPS cell lines generated from four individuals of a family of genetically unrelated parents and their female monozygotic twins



Marga J Bouma<sup>a</sup>, Christian Freund<sup>a</sup>, Adriaan P IJzerman<sup>b</sup>, Dorret I Boomsma<sup>c</sup>,  
Christine L Mummery<sup>a</sup>, Karine Raymond<sup>a,\*</sup>

<sup>a</sup> LUMC human iPSC Hotel, Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, 2333 ZC, the Netherlands

<sup>b</sup> Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, PO Box 9502, 2300 RA, Leiden, the Netherlands

<sup>c</sup> Department of Biological Psychology, VU University Amsterdam, Neuroscience Amsterdam, Amsterdam, the Netherlands

## A B S T R A C T

Lymphoblast cells from four individuals of a family of two genetically unrelated parents and their monozygotic twins were used to generate integration-free human induced pluripotent stem cells (hiPSCs). Reprogramming factors were delivered by co-electroporation of three episomal-based plasmids expressing OCT3/4, SOX2, KLF4, L-MYC and LIN28. The hiPSCs showed a normal karyotype, expressed pluripotency-associated markers, displayed the capacity for *in vitro* differentiation into the three germ layers and were Epstein Barr virus-free. These hiPSC lines offer the possibility to compare genetically unrelated and genetically identical tissues from different individuals and to study genotype-specific effects, which are particularly relevant for toxicology testing.

## Resource Table

Unique stem cell lines identifier	LUMCi013-A LUMCi014-A LUMCi015-A LUMCi016-A	Name of transgene or resistance	
Alternative names of stem cell lines	L01 (LUMCi013-A) L02 (LUMCi014-A) L03 (LUMCi015-A) L04 (LUMCi016-A)	Inducible/constitutive system	NA
Institution	LUMC hiPSC Hotel, Department of Anatomy and Embryology, Leiden University Medical Center, Einthovenweg 20, 2333 ZC Leiden, The Netherlands	Date archived/stock date	29/10/2019
Contact information of distributor	Karine Raymond (k.i.Raymond@lumc.nl)	Cell line repository/bank	NA
Type of cell lines	hiPSC	Ethical approval	Ethical committees and approval numbers: —Central Ethics Committee on Research Involving Human Subjects of the VU University Medical Centre, Amsterdam, an Institutional Review Board certified by the U.S. Office of Human Research Protections (IRB number IRB00002991 under Federal-wide Assurance-FWA00017598; IRB/institute codes, NTR 03-180), under the IRB reference 2003t180. LUMC CME under the protocol #P13.080
Origin	Human		
Cell Source	Human lymphoblast cells		
Clonality	Clonal		
Method of reprogramming	Non-integrating episomal vectors pCXLE-hOCT3/4 (Addgene ID 27076) pCXLE-hSK (Addgene ID 27078) pCXLE-hUL (Addgene ID 27080)		
Multiline rationale	Cell lines from monozygotic twins (genetically identical) and their parents (genetically unrelated)		
Gene modification	NO		
Type of modification	NA		
Associated disease	NA		
Gene/locus	NA		
Method of modification	NA		

## 1. Resource utility

The hiPSC lines here originate from transformed lymphocyte cells derived from female monozygotic twins and their parents (Willemssen et al., 2010), making it possible to generate genetically -identical and -unrelated tissues. By comparing the response of twin's, the lines are useful for studying genotype-related effects notably in toxicology.

\* Corresponding author.

E-mail address: [k.i.raymond@lumc.nl](mailto:k.i.raymond@lumc.nl) (K. Raymond).

<https://doi.org/10.1016/j.scr.2019.101654>

Received 1 November 2019; Accepted 6 November 2019

Available online 08 November 2019

1873-5061/ © 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Table 1**  
Summary of lines.

hiPSC line names	Abbreviation in figures	Gender	Age	Ethnicity	Genotype of locus	Disease
	L01	Male	75	Caucasian	N/A	N/A
	L02	Female	70	Caucasian	N/A	N/A
	L03	Female	36	Caucasian	N/A	N/A
	L04	Female	36	Caucasian	N/A	N/A

### 1.1. Resource details

Lymphoblast cell lines (LCLs) are derived from donor B-lymphocytes by Epstein Bar virus (EBV) transformation and represent a useful cell type for storing genetic material and examining the influence of genetic variations on drug response (Hillger et al., 2015). In this study, LCLs derived from a family of adult monozygotic twins and their parents were used to generate hiPSCs (Table 1). The LCLs had previously been generated at the Rutgers Institute (Department of Genetics, Piscataway, NJ, USA) using a standard transformation protocol (Willemssen et al., 2010; Hillger et al., 2015).

For reprogramming, LCLs were electroporated with oriP/EBNA-1-based episomal plasmids expressing OCT3/4, SOX2, KLF4, L-MYC and LIN28 (Okita et al., 2011). Individual hiPSC colonies were mechanically picked and the corresponding hiPSC lines were expanded at least to passage 10. hiPSCs displayed characteristic epithelial morphology with compact, dense colonies with sharp edges and containing cells with a high nucleus-to-cytoplasm ratio (Fig. 1A). The pluripotency status of the iPSC lines was confirmed by expression of the pluripotency markers OCT3/4, NANOG and SSEA4 evidenced by immunofluorescent staining (Fig. 1B) and by flow cytometry (Fig. 1C). G-banding karyotyping revealed that all lines had normal diploid karyotype (Fig. 1D). The pluripotent differentiation potential of the lines was verified by *in vitro* spontaneous differentiation towards the three germ layers, as shown by immunofluorescent staining of the ectodermal marker  $\beta$ III-tubulin (B3-TUB), the endodermal marker  $\alpha$ -fetoprotein (AFP) and the mesodermal marker platelet endothelial cell adhesion molecule-1 (PECAM-1) (Fig. 1E). The identity of the hiPSC lines was confirmed by short tandem repeat (STR) analysis, which matched that of the original LCLs. Interestingly, EBV-related latency elements necessary for the transformation of B cells to LCLs were lost from the hiPSC-derived lines as assessed by PCR (Fig. 1F). The complete characterization is summarized in Table 2.

## 2. Materials and methods

### 2.1. Cell culture

The LCLs were cultured in expansion medium (EM) composed of RPMI-1640 (Sigma-Aldrich, #R5886) supplemented with 15% fetal bovine serum (FBS) (Gibco, #10270), 2 mM L-Glutamin (Gibco#15070), 50  $\mu$ g/mL streptomycin and 50 U/mL penicillin (Gibco, #25030) at 37 °C and 5% CO<sub>2</sub>.

### 2.2. iPSC line generation

LCLs at passage 50 were reprogrammed by the Leiden University Medical Center (LUMC) Human iPSC Hotel, as previously described (Barret et al., 2016) with minor modifications. Briefly,  $1 \times 10^6$  cells were electroporated with 1  $\mu$ g of each of the episomal plasmids pCXLE-hOCT3/4, pCXLE-hSK and pCXLE-hUL (Addgene, #ID27076, #ID27078, #ID27080) with the program E-010 of the Nucleofector™ I device and the B-cell Nucleofector Kit (VPA-1001, Lonza). Cells were subsequently plated at a density of  $3.5 \times 10^4$  cells/cm<sup>2</sup> on Matrigel™-coated plates (Corning/BD Biosciences, #354277) in EM for 3 days. For

the next 3 days, 1 ml of reprogramming media (RM; supplemented ReproTeSR Basal medium (Stemcell Technologies, #05921, #05922, #05923)) was added daily to the original LCL media. For the following 11 days the cells were maintained in RM with daily media replenishment and the media was changed to TeSR™-E8™ (Stemcell Technologies, #05990) after day 18. After mechanical picking, iPSCs were maintained in TeSR™-E8™ on vitronectin-coated plates (Stemcell Technologies, #07180) at 37 °C and 5% CO<sub>2</sub>.

### 2.3. Immunofluorescence staining

Cells were fixed using 1% paraformaldehyde for 30 min at 25 °C and permeabilized and blocked using 0.1% TritonX-100 in PBS containing 4% normal swine serum (Jackson ImmunoResearch, #014-000-121) for 1 h at 25 °C. Cells were incubated with primary and secondary antibodies (Table 3) in PBS for 1 h at 25 °C. Washes were performed with 0.05% Tween in PBS. Nuclei were stained with DAPI (Fisher Scientific, #D3571) and images were taken with a SP5 confocal microscope (Leica).

### 2.4. Flow cytometry analysis

Cells were dissociated into single cells with Gentle Cell dissociation reagent (7 min at 37 °C, Stemcell Technologies, #07174), and fixed and permeabilized by using the FIX & PERM™ Cell Permeabilization kit (ThermoFisher, #GAS004), according to the manufacturer's instructions. Cells were incubated with the antibodies (Table 3) for 20 min in the dark at 25 °C and analyzed with a LSRII flow cytometer (BD) The HaCaT keratinocyte cell line was used as a negative control.

### 2.5. Karyotype analysis

G-banding analysis was conducted at the Laboratorium voor Diagnostische Genoanalyse (LGDA), LUMC according to standard procedures. A total of 20 metaphases were analyzed for each line.

### 2.6. Induction of differentiation

The hiPSCs were passaged and maintained for three days on vitronectin-coated glass coverslips in TeSR™-E8™ and subsequently cultured in DMEM/F12 (Gibco, #31331-028) containing 20% FBS for 3 weeks with media changes every two days.

### 2.7. Genome analysis of the EBV-related latency elements


Genomic DNA was extracted from iPSCs using QuickExtract™ DNA Extraction solution (Lucigen, #QE09050) and PCR was performed by using Terra Taq polymerase (Takara, #639270) with previously described conditions (Barrett et al., 2014). Comment: Are LMP1, BZLF1 etc. described somewhere in the references? You show them in the PCR but if there is no fig legend it may be unclear what they stand for. Legend added and genes described in Barrett et al., 2014

### 2.8. Short tandem repeat (STR) analysis

Cell line authentication was performed by the Department of Human Genetics, LUMC, by using the PowerPlex® Fusion System 5C autosomal STR kit (Promega) as previously described (Westen et al., 2014).

### 2.9. Mycoplasma detection

The mycoplasma status was assessed using the MycoAlert™ mycoplasma detection kit (Lonza, #LT07-418) following the manufacturer's protocol.



(caption on next page)



**Fig. Characterization of the LUMCi013-A (L01), LUMCi014-A (L02), LUMCi015-A (L03) and LUMCi016-A (L04) hiPSC lines.** A, Colonies display typical morphology of hiPSCs maintained in TeSR™ E8™ on vitronectin-coated plates. B, Pluripotency markers detected by immunofluorescent staining. hiPSC colonies are positive for OCT3/4 (green), NANOG (red) and SSEA4 (green) pluripotency markers. C, Pluripotency markers analyzed by flow cytometry. More than 80% of the cells maintained in TeSR™ E8™ on vitronectin-coated plates, are positive for the OCT3/4 and SSEA4 pluripotency markers. D, G-banding karyotyping indicate normal diploid karyotypes. E, Spontaneous differentiation *in vitro*. Cells can differentiate towards the three germ layers, as shown by immunofluorescent staining of the ectodermal marker B3-TUB (red), the endodermal marker AFP (green) and the mesodermal marker PECAM-1 (red). F, Analysis of Epstein Barr virus-related genes (EBNA-1, EBNA-2, LMP-1, BZLF-1, and OriP) by PCR of genomic DNA obtained from parental LCL (LCL), from daughter iPSC lines (L01, L02, L03 and L04), and from negative control lines (human keratinocyte cell lines (Hacat) and independent hiPSC line (hiPSC)). GAPDH is used as a loading control.

**Table 2**  
Characterization and validation.

Classification	Test	Result	Data
Morphology	Transmission light microscopy	Normal	Fig. 1A
Phenotype	Pluripotency status, qualitative analysis: Immunofluorescent staining	All the lines showed positive staining of pluripotency markers: Oct3/4, NANOG, SSEA4.	Fig. 1B
	Pluripotency status, quantitative analysis: flow cytometry	Percentage of cells positives for Oct3/4 and SSEA-4: L01 (84%); L02 (81%); L03 (85%) and L04 (81%)	Fig. 1C
Genotype	Karyotype (G-banding) Resolution 450–500	L01 (46,XY); L02 (46,XX); L03 (46,XX) and L04 (46,XX)	Fig. 1D
Identity	Microsatellite PCR (mPCR) OR STR analysis	Not performed 22 sites tested, all sites matched	N/A Submitted in archive with journal
Mutation analysis (IF APPLICABLE)	Sequencing	N/A	N/A
	Southern Blot OR WGS	N/A	N/A
Microbiology and virology	Luminescence-based mycoplasma testing.	Negative.	Submitted in archive with journal
	Detection of Epstein Barr virus-related latency elements by PCR.	Negative.	Fig. 1F
Differentiation potential	Pluripotency function; spontaneous differentiation	Expression of ectodermal marker b3-tubulin (B3-TUB), endodermal marker alpha-fetoprotein (AFP) and mesodermal marker platelet endothelial cell adhesion molecule-1 (PECAM-1) was detected.	Fig. 1E
Donor screening (OPTIONAL)	HIV 1 + 2 Hepatitis B, Hepatitis C	Not performed	N/A
Genotype additional info (OPTIONAL)	Blood group genotyping	Not performed	N/A
	HLA tissue typing	Not performed	N/A

**Table 3**  
Reagents details.

Antibodies used for immunocytochemistry/flow-cytometry			
	Antibody	Dilution	Company Cat # and RRID
Pluripotency Markers	mouse IgG2b anti-OCT3/4	1:100	Santa Cruz, Sc-5279
Pluripotency Markers	mouse IgG1 anti-NANOG	1:150	Santa Cruz, Sc-293,121
Pluripotency Markers	mouse IgG3 anti-SSEA4	1:30	Biolegend, #330402
Pluripotency Markers	BV421 Mouse IgG1 anti-OCT3/4	1:50	BDBioscience, AB#565644
Pluripotency Markers	FITC Human IgG1 anti-SSEA4	1:25	Miltenyi, #130-098-371
Differentiation Markers	mouse IgG2ba anti-b3-tubulin	1:4 000	Covance, #MMS-435P
Differentiation Markers	rabbit anti-AFP	1:25	Quartett, #2011200530
Differentiation Markers	mouse IgG1 anti-PECAM-1	1:100	DAKO, #M0823
Secondary antibodies	Alexa 647 Goat Anti-Mouse IgG2b	1:250	Invitrogen Cat# 21242
Secondary antibodies	Alexa 488 Goat Anti-Mouse IgG3	1:250	Invitrogen Cat# 21151
Secondary antibodies	Alexa 568 Goat Anti-Mouse IgG1	1:250	Invitrogen Cat# 21124
Secondary antibodies	Alexa 568 Goat Anti-Mouse IgG	1:500	Invitrogen Cat# A11031
Secondary antibodies	Alexa 488 Donkey Anti-rb IgG	1:500	Invitrogen Cat# A21206
Primers	Target	Forward/Reverse primer (5'-3')	
EBV-related latency elements (genomic PCR)	EBNA-1	ATCAGGGCCAAGACATAGAGA/ GCCAATGCAACTTGGACGTT	
EBV-related latency elements (genomic PCR)	EBNA-2	CATAGAAGAAGAAGAGGATGAAGA/ GTAGGGATTTCGAGGGAATTACTGA	
EBV-related latency elements (genomic PCR)	BZLF-1	CACCTCAACCTGGAGACAAT/ TGAAGCAGGCGTGGTTTCAA	
EBV-related latency elements (genomic PCR)	LMP-1,	ATGGAACACGACCTTGAGA/ TGAGCAGGATGAGGTCTAGG	
EBV-related latency elements (genomic PCR)	OriP	TCGGGGGTGTTAGAGACAAC/ TTCCACGAGGGTAGTGAACC	
House keeping gene (genomic PCR)	GAPDH	ACCACAGTCCATGCCATCAC/ TCCACCACCTGTTGTCTGTA	

## Declaration of Competing Interest

The authors declare no conflict of interest.

## Acknowledgments

We would like to thank the Department of Human Genetics, LUMC, for the STR DNA analysis and the Laboratorium voor Diagnostische Genoomanalyse (LGDA), LUMC, for the karyotyping analysis. This work was supported by the Netherlands Organ-on-Chip Initiative, an NOW Gravitation project funded by the Ministry of Education, Culture and Science of the government of the Netherlands (024.003.001).

## Supplementary materials

Supplementary material associated with this article can be found, in the online version, at [doi:10.1016/j.scr.2019.101654](https://doi.org/10.1016/j.scr.2019.101654).

## References

- Willemsen, G., de Geus, E.J., Bartels, M., van Beijsterveldt, C.E., Hottenga, J.J., Kluit, K., Meijer, P., Montgomery, G.W., Rizzu, P., Sondervan, D., Smit, A.B., Spijker, S., Suchiman, H.E., Tischfield, J.A., Lehner, T., Slagboom, P.E., Boomsma, D.I., 2010. The Netherlands Twin Register biobank: a resource for genetic epidemiological studies. *Twin Res. Hum. Genet.* 13, 231–245.
- Hillger, J.M., Schoop, J., Boomsma, D.I., Slagboom, P.E., IJzerman, A.P., Heitman, L.H., 2015. Whole-cell biosensor for label-free detection of GPCR-mediated drug responses in personal cell lines. *Biosens. Bioelectron.* 74, 233–242.
- Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K., Shibata, T., Kunisada, T., Takahashi, M., Takahashi, J., Saji, H., Yamanaka, S., 2011. A more efficient method to generate integration-free human iPS cells. *Nat. Methods* 8, 409–412.
- Barrett, R., Ornelas, L., Yeager, N., Mandefro, B., Sahabian, A., Lenaues, L., Targan, S.R., Svendsen, C.N., Sareen, D., 2014. Reliable generation of induced pluripotent stem cells from human lymphoblastoid cell lines. *Stem Cells Transl. Med.* 3, 1429–1434.
- Westen, A.A., Kraaijenbrink, T., Robles de Medina, E.A., Harteveld, J., Willemse, P., Zuniga, S.B., van der Gaag, K.J., Weiler, N.E., Warnaar, J., Kayser, M., Sijen, T., de Knijff, P., 2014. Comparing six commercial autosomal STR kits in a large Dutch population samples. *Forensic Sci. Int. Genet.* 10, 55–63.